

## Day 1 Stream 1 – Artificial Intelligence (AI) in Drug Discovery and Development

- Drug Development based on biological markers
- Machine learning and Data Analysis
- High-throughput screening and AI
- AI in Platforms and tools: supporting modelling and real world data teams and research labs globally
- Genomics, Big Data Analysis and Deep Learning for In Silico Drug Discovery and Drug Repurposing for Aging and Age-related diseases
- AI in Drug Design

## Day 2 Stream 1 – Part 1 Artificial Intelligence (AI) in Big Data and Clinical Research Development

- Patient Stratification in clinical trials
- Applying Machine Learning and Data Analytics to clinical trial data
- AI in Cloud computing and Big data
- Supporting Real World Evidence and E Health Support
- AI, Robotics and Machine Learning: leading data science and machine learning teams working across therapeutic areas in the late stage drug development pipeline

## Day 2 Stream 1 – Part 2 Diagnostics and Medical Imaging in Healthcare

- AI in Medical Imaging and Diagnostics
- AI in Remote patient monitoring and Healthcare: biosensor data and patient-specific alerts to clinicians

## Meet Senior Decision Makers

200 VPs, Directors & Senior Managers from leading pharmaceutical organisations, biotech companies and academic institutions will attend the event. Delegate job titles

Artificial Intelligence	Advanced Analytics
Computational Chemistry	Scientific Computing
Robotics	Modelling Platforms
Bioinformatics	Computational Biology
Medical IT	Machine Learning
Drug Design	Drug Development
Data Analysis	Deep Learning
Cloud Computing	Medical Imaging
Healthcare Diagnostics	Biosensors

## Discover New Solutions

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers. Services to be discussed include:

AI Algorithms	AI Tools
Bioinformatics	Machine Learning Tools
Robotics	Cloud Computing
IT Solutions	Software Solutions
Computational Models	Data Analysis

## Benefits to Attending

- ✓ **Hear from and meet with the key innovators in Artificial Intelligence**, including AstraZeneca, MSD, F. Hoffman-La Roche, Janssen, Sanofi-Pasteur and Novartis
- ✓ **Discover collaborative solutions to the use of Artificial Intelligence in Drug Development**
- ✓ **Explore the latest applications of Artificial Intelligence through case studies on:** Biomarker Discovery and Development; Machine learning and Data Analysis; AI in Platforms and Tools; and Deep Learning for in silico drug discovery
- ✓ **Unparalleled networking opportunities.** The two-day congress offers dedicated networking breaks creating an interactive platform for scientific discussions, 1-1 meetings and our popular drinks reception. The exhibition hall and poster presentation spaces offer a relaxed and professional environment for discussion
- ✓ **A stratified program ensuring tailored content** – Benefit from attending pre-event webinars, panel discussions and roundtable discussions
- ✓ **Co-located with the well-established 15<sup>th</sup> Annual Pharmaceutical IT Congress**

## Complimentary registration to our pre-event webinars

**Thursday 1<sup>st</sup> June 2017, 2pm BST:**

**Harnessing AI And Big Data In Drug Discovery**

Hosted by Ed Addison, Chairman and CEO, Cloud Pharmaceuticals.

[Register Here>>](#)

**Tuesday 6<sup>th</sup> June 2017, 2pm BST:**

**'The Impact Of Structure Based Drug Design And Computational Analysis On The Timeframes Of Drug Development'**

Hosted by Rafael Depetris, Principal Scientist I, Kadmon Corporation.

[Register Here>>](#)

## 2017 Speakers Include:



**James Weatherall,**  
AstraZeneca



**Ian Smith**  
MSD



**Kevin Hua**  
Bayer LifeScience iHub



**Eliud Oloo**  
Sanofi-Pasteur



**Thomas Herz**  
4SC AG



**Jackie Hunter**  
Benevolent Bio

For booking details & registration fees please refer to the last page or visit:

<http://www.artificialintelligence-congress.com/>

#### Artificial Intelligence in Drug Development Confirmed and Reserved speakers 2017:

- James Weatherall, Executive Director and Head of Advanced Analytics Centre, AstraZeneca
- David Ruau, Head of Scientific Computing Solutions, AstraZeneca
- Martin Strahm, Head of Data Science, F. Hoffman-La Roche
- Hugo Ceulemans, Head of Discovery Data Sciences Unit, Janssen
- Raj Bandaru, Senior Director, Integrated Pharmacology, Sanofi
- Ian Smith, Director – Scientific Modelling Platforms, MSD
- David Ohlssen, Biometrical Fellow and Advanced Analytics Lead, Novartis
- Jackie Hunter, CEO, Benevolent Bio
- Ed Addison, Chairman and CEO, Cloud Pharmaceuticals
- Blake Borgeson, Co-founder and CTO, Recursion Pharmaceuticals
- Thomas Herz, Senior Manager Bioinformatics, 4SC AG
- Kevin Hua, Sr. Manager A.I./Machine Learning Development, Bayer LifeScience iHub
- Eliud Oloo, Manager, Innovation Programs in Structural Biology, Sanofi-Pasteur
- Andrea Splendiani, Sr. Knowledge Engineering Consultant, Novartis
- Marian Klug, Project Lead, Bayer
- Rafael Depetris, Principal Scientist I, Kadmon Corporation
- Alex Gammerman, Professor of Computer Science, Computer Learning Research Centre, Royal Holloway University of London
- Lars Carlsson, Team Leader, Quantitative Biology, AstraZeneca
- Enrico Ferrero, Associate GSK Fellow and Scientific Leader, Computational Biology and Statistics, Target Sciences, GlaxoSmithKline
- Alvaro Cortes, Computational Chemist, GlaxoSmithKline

#### Co-located Pharmaceutical IT Congress Confirmed Speakers 2017 Include:


- Philip Hajduk, Vice President, R&D Information Research, AbbVie
- M. Hall Gregg, Vice President, Business Technology, Pfizer
- Emmanuel Pham, Vice President Biometry, Ipsen
- Sandy Farmer, Executive Director, Department of Genome Sciences & Technologies, Pfizer Worldwide R&D
- Chad Dau, Senior Director, Real World Informatics & Analytics Services, Astellas
- Margaret McDonald, Senior Director, Real World Data and Analytics, Global Health and Value, Pfizer
- Claus Bendtsen, Director and Head of Quantitative Biology, AstraZeneca
- Christine Buesnel, Director, Product Development, Biometrics, Roche/Genentech
- Jay Bergeron, Director, Translational and Bioinformatics, Pfizer
- Lars Greiffenberg, Director, R&D IT and Translational Informatics, AbbVie
- Oliver Hesse, Director, Lab Automation & Data Management, Bayer
- Nigel Hughes, Scientific Director, Janssen R&D
- Pantaleo Nacci, Director, Statistical Programming, AstraZeneca
- Raphaël Pousset-Bougère, Big Data and Analytics Director, Ipsen
- Simon Thornber, Director of Analytics, GlaxoSmithKline
- Dragan Vuksanovic, Director, Enterprise Architecture, Biogen
- Matthew Bonam, Pharmaceutical Project Director, Intelligent Pharmaceuticals, AstraZeneca
- Christian Gossens, Global Head, pRED Development Team, Roche
- Juergen Hammer, Global Head Data Science, Roche
- Peter Speyer, Global Head of Real World Evidence Solutions, Novartis
- Etzard Stolte, Global Head, Knowledge Management, Roche
- Andrew Garrood, Global Lead, New Technologies Client Devices, Novartis
- Roman Affentranger, Head, Small Molecule Discovery Workflows, F. Hoffmann-La Roche
- Hugo Ceulemans, Head Discovery Data Sciences, Janssen
- Akanksha Gupta, Head of Translational Science, GlaxoSmithKline
- Alaa Hamed, Head, Global Evidence and Value Development, Genzyme Sanofi
- Jan Hauß, Head of R&D LIMS, IT-Manager, Merck KGaA
- Alexander Krupp, Head of Computational Life Science IT Pharmaceuticals, Bayer
- Vinay Kuntamukkala, Head of BI & Analytics, EU+, Biogen
- Thorsten Naumann, Head, Hub Management Office R&D Hub Germany, Sanofi Aventis
- Richardus Vonk, Head of Research & Clinical Sciences Statistics, Bayer Pharma AG
- Christine Veyrat-Follet, Deputy Head Translational Informatics, Sanofi
- Diederik Schweitzer, IT-Business Partner, MSD
- Angeli Möller, IT Business Partner for Clinical Sciences, Bayer
- Francis Kendall, Digital Strategy Leader, Roche
- Henning Kayser, R&D IT - Global Lab Solutions, Bayer
- Michael R Barnes, Reader and Director of Bioinformatics, Centre for Translational Bioinformatics, Queen Mary University of London
- Emanuele de Rinaldis, Head of Translational Bioinformatics, NIHR Biomedical Research Centre
- Timo Minssen, Professor of Biotechnology Law, University of Copenhagen
- Vivian Vimarlund, Professor in Informatics, Linköping University

#### 2017 Artificial Intelligence in Drug Development and Pharmaceutical IT Congress Confirmed Sponsors Include:



For more information please contact [marketing@oxfordglobal.co.uk](mailto:marketing@oxfordglobal.co.uk)

**Artificial Intelligence in Drug Development Congress  
Day One – 27<sup>th</sup> September 2017**

07.30 – 08.20	<b>Registration</b>
08.20 – 08.25	<b>Oxford Global's Welcome Address</b>
08.25 – 08.30	<b>Chairperson's Opening Address</b>
	<b>Artificial Intelligence (AI) In Drug Discovery And Development</b>
08.30 – 09.00	<p><b>Keynote Address: Can AI Really Disrupt Drug Discovery And Development?</b></p> <ul style="list-style-type: none"> <li>The process of drug discovery and development has essentially remained static for the past few decades and the current failure rates and cost are becoming unsustainable</li> <li>Benevolent Bio is applying AI and machine learning at several points along the R&amp;D process to improve the efficiency and cost effectiveness of the discovery and development of new medicines</li> <li>Examples of the application of this exciting technology will be discussed</li> </ul> <p><b>Jackie Hunter, CEO, Benevolent Bio</b></p>
09.00 – 09.30	<p><b>Phenotypic Profiling Of Compounds: Deciphering The Mode Of Actions</b></p> <p><b>Martin Strahm, Head of Data Science, Roche</b></p>
09.30 – 10.00	<p align="center"><b>Solution Provider Presentation</b></p> <p><b>Machine Learning In Drug Discovery – Application Of Cross-industry Innovation</b></p> <ul style="list-style-type: none"> <li>A discussion and review of practical steps that an enterprise can take to realise the most value from AI/machine learning; from data management, identifying the correct tool for the correct job and the importance of speed and agility in maximizing the value from data science, contemporary AI and data science</li> <li>Examples and case studies of cross-industry data science innovations we applied to life science data challenges</li> </ul> <p><b>Matt Jones, Lead Analytics Strategist, Tessella</b></p> 
10.00 – 11.20	<b>Morning Coffee &amp; Refreshments, One to One Meetings x3, Poster Presentation Sessions</b>
11.20 – 11.50	<p><b>Application Of AI And Machine Learning To Vaccine Development</b></p> <ul style="list-style-type: none"> <li>Describe the challenges of designing vaccines targeted at constantly evolving pathogens</li> <li>Offer insights into the practical application of AI and Machine Learning to the design and development of novel vaccine antigens.</li> </ul> <p><b>Eliud Oloo, Manager, Innovation Programs in Structural Biology, Sanofi-Pasteur</b></p>
11.50 – 12.20	<p><b>In Silico Prediction Of Novel Therapeutic Targets Using Gene – Disease Association Data</b></p> <ul style="list-style-type: none"> <li>Target identification and validation is a pressing challenge in the pharmaceutical industry, with many of the programmes that fail for efficacy reasons showing poor association between the drug target and the disease</li> <li>We use a semi-supervised classification approach to explore whether gene-disease association data from the Open Targets platform is sufficient to predict therapeutic targets that are actively being pursued by pharmaceutical companies or are already on the market</li> <li>We show that a neural network is able to predict therapeutic targets with over 70% accuracy demonstrating that disease association is predictive of the ability of a gene or a protein to work as a drug target</li> </ul> <p><b>Enrico Ferrero, Associate GSK Fellow and Scientific Leader, Computational Biology and Statistics, Target Sciences, GlaxoSmithKline</b></p>
12.20 – 12.50	<p align="center"><b>Solution Provider Presentation</b></p> <p align="center">For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a></p>
12.50 – 13.50	<b>Lunch</b>
13.50 – 14.20	<p><b>Using AI Combined With Computational Chemistry To Design Drugs</b></p> <ul style="list-style-type: none"> <li>HTS is the "Emperor with no clothes"</li> <li>When computational chemistry made its first run 15-20 years ago, computer power was inadequate for acceptable performance</li> <li>Today, the confluence of AI, big data and more advanced computational chemistry is disrupting HTS</li> <li>A variety of AI methods will be presented: virtual chemical space, heuristic search, expert systems and machine learning</li> </ul> <p><b>Ed Addison, CEO, Cloud Pharmaceuticals</b></p>
14.20 – 14.50	<p><b>HTS And AI Converge To Disrupt Discovery</b></p> <p><b>Blake Borgeson, Co-founder and CTO, Recursion Pharmaceuticals</b></p>
14.50 – 15.20	<p align="center"><b>Solution Provider Presentation</b></p> <p align="center">For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a></p>
15.20 – 16.20	<b>Afternoon Refreshments, One to One Meetings x3, Poster Presentation Sessions</b>

**Artificial Intelligence in Drug Development Congress  
Day One – 27<sup>th</sup> September 2017**

<b>Artificial Intelligence (AI) in Drug Discovery And Development</b>	
<b>16.20 – 16.50</b>	<p><b>Pre-Panel Discussion: The Omics Challenge – Thoughts And Ideas For Drug Development In The Big Data And AI Era</b></p> <p><b>Thomas Herz, Senior Manager Bioinformatics, 4SC AG</b></p>
<b>16.50 – 17.20</b>	<p><b>Panel Discussion: Drug Development Through Big Data And AI</b></p> <p><b>Panel Moderator: Thomas Herz, Senior Manager Bioinformatics, 4SC AG</b></p>
<b>17.20 – 17.50</b>	<p><b>Company Case Study: Title To Be Confirmed</b></p> <p><b>Alvaro Cortes, Computational Chemist, GlaxoSmithKline</b></p>
<b>17.50 – 18.20</b>	<p><b>Conformal Predictors In Drug Discovery</b></p> <p>This talk presents an application of <b>conformal predictors</b> (CP) – a recently developed machine learning method – to the large, high-dimensional, sparse and imbalanced data sets. The classical machine learning techniques usually provide a bare prediction; CP method allows us to make <b>hedged predictions</b> by providing some additional information. The advantages in using this technique include:</p> <ol style="list-style-type: none"> <li>1. CP will supply the <b>valid</b> measures of confidence in the prediction of bioactivities of the compounds</li> <li>2. They can provide prediction and confidence for <b>individual</b> compounds</li> <li>3. CP can allow the <b>ranking</b> of compounds to optimize the experimental testing of given samples</li> <li>4. The user can <b>control</b> the number of errors and other performance measures by setting up a required level of confidence in the prediction</li> </ol> <p>The approach allows us to select active and non-active compounds; the results are presented and discussed.</p> <p><b>Alex Gammerman, Professor of Computer Science, Computer Learning Research Centre, Royal Holloway University of London</b></p> <p><b>Lars Carlsson, Team Leader, Quantitative Biology, AstraZeneca</b></p>
<b>18.20 – 18.50</b>	<p><b>Devising The Mechanism Of Action Of Therapeutic Antibodies Through Computational Analysis: A Case Study</b></p> <ul style="list-style-type: none"> <li>• Present an example of how molecular modelling leads to a thorough understanding of the mechanism of action of a therapeutic antibody</li> <li>• Discuss the proper methods for model validation</li> <li>• Present an overview of the achievements obtained in the development of therapeutic agents by structure based design</li> </ul> <p><b>Rafael Depetris, Principal Scientist I, Kadmon Corporation, LLC.</b></p>
<b>18.50 – 19.20</b>	<i>Delegates are welcome to attend co-located presentations</i>
<b>19.20 – 19.50</b>	<i>Delegates are welcome to attend co-located presentations</i>
<b>19.50</b>	<b>Networking Drinks &amp; End of Day One</b>



**Artificial Intelligence in Drug Development Congress  
Day Two – 28<sup>th</sup> September 2017**

<b>Artificial Intelligence (AI) In Big Data And Clinical Research Development</b>	
<b>08.30 – 09.00</b>	<p><b>Keynote Address: Unlocking The Power Of Exploratory Analytics In Clinical Research</b></p> <ul style="list-style-type: none"> <li>The growing area of data science has placed greater focus on visualization, predictive analytics and machine learning</li> <li>This is in contrast to a drug development setting, where biostatisticians have tended to focus on techniques suited to the confirmatory phase III paradigm, even when dealing with questions that are more exploratory in nature</li> <li>Tukey, who emphasized the need for both exploratory and confirmatory paradigms, forcefully argued that in science important and relevant questions are generated from data exploration. He went on to refute the notion that exploratory analysis is just descriptive statistics, stating that it is an attitude, requiring flexibility, and a reliance on display but not a bundle of techniques</li> <li>How can the thoughts of Tukey be combined with the latest developments in data science to improve exploratory analysis in drug development</li> <li>In this talk, we aim to examine this question through a series of case-studies</li> <li>Recent developments in dynamic visualization, machine learning and software tools will be discussed</li> </ul> <p><b>David Ohlssen, Biometrical Fellow and Advanced Analytics Lead, Novartis</b></p>
<b>09.00 – 09.30</b>	<p><b>Massive Scale Machine Learning Integrating Chemical Structures And High-throughput Data Across Partners For The Prediction Of Compound Activity</b></p> <ul style="list-style-type: none"> <li>The leap from single-assay QSAR models for lead optimization to more broadly applicable multi-task models that span thousands of assays at once</li> <li>Untapped high throughput microscopy-based, cytometry and transcriptomic screens complement chemical structures to inform machine learning</li> <li>The move from data federation to analysis federation: massive-scale learning across industrial partners without disclosure of the underlying data</li> </ul> <p><b>Hugo Ceulemans, Head of Discovery Data Sciences Unit, Janssen</b></p>
<b>09.30 – 10.00</b>	<p><b>Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a></p>
<b>10.00 – 11.00</b>	<b>Morning Coffee &amp; Refreshments, One to One Meetings x2, Poster Presentation Sessions</b>
<b>11.00 – 11.30</b>	<p><b>Artificial Intelligence &amp; Machine Learning Applications In Clinical Development: Present &amp; Future</b></p> <ul style="list-style-type: none"> <li>Machine learning as applied to the intelligent mining of clinical trials data</li> <li>Predictive analytics to refine the operational execution of drug development</li> <li>The challenges &amp; opportunities presented by the burgeoning role of technology in clinical research</li> <li>A glimpse to the future: how AI might be used in years to come</li> </ul> <p><b>James Weatherall, Executive Director and Head of Advanced Analytics Centre, AstraZeneca</b></p>
<b>11.30 – 12.00</b>	<p><b>Solution Provider Presentation</b> For sponsorship opportunities please contact <a href="mailto:sponsorship@oxfordglobal.co.uk">sponsorship@oxfordglobal.co.uk</a></p>
<b>12.00 – 12.30</b>	<p><b>Company Case Study: Utilising Machine Learning And Data Analytics</b></p> <p><b>Ian Smith, Director – Scientific Modelling Platforms, MSD</b></p>
<b>12.30 – 13.30</b>	<b>Lunch</b>
<b>13.30 – 14.00</b>	<p><b>Panel Discussion: Unlocking Data Collaboration Innovation Using AI</b></p> <ul style="list-style-type: none"> <li>How can AI help unlock 'siloe'd' data?</li> <li>Enabling data entitlements to improve integrity and traceability with AI</li> <li>How can we address industry resistance to collaboration – culture or technology?</li> <li>Using data entitlements to empower data transparency and trust</li> </ul> <p><b>Panel Moderator: Ian Smith, Director – Scientific Modelling Platforms, MSD</b></p>
<b>14.00 – 14.30</b>	<p><b>Applying Machine Learning To Clinical Data And Implementing Data Analytics</b></p> <p><b>David Ruau, Head of Scientific Computing Solutions, AstraZeneca (RESERVED)</b></p>
<b>14.30 – 15.00</b>	<p><b>Company Case Study: AI To Improve Clinical Trials</b></p> <ul style="list-style-type: none"> <li>We use AI, especially machine learning/data mining technology, to help speed up clinical trials</li> <li>With AI, we can help clinical scientists make data-driven decisions and reach conclusions faster and more accurately, such as prediction of medical conditions of subjects for enrollment selection and prediction of potential adverse event of new drugs based on historical trials</li> <li>AI can not only accelerate clinical trials, but also help reduce the risks and costs associated with clinical trials</li> <li>AI technology plays a crucial role in future clinical trials</li> </ul> <p><b>Kevin Hua, Sr. Manager A.I./Machine Learning Development, Bayer LifeScience iHub</b></p>
<b>15.00 – 15.30</b>	<b>Afternoon Refreshments, Poster Presentation Sessions</b>
<b>15.30 – 16.00</b>	<p><b>A Combination Of Machine Learning And Symbolic Methods For Data Curation</b></p> <p><b>Andrea Splendiani, Sr. Knowledge Engineering Consultant, Novartis</b></p>

**Artificial Intelligence in Drug Development Congress  
Day Two – 28<sup>th</sup> September 2017**

	<b>Diagnostics And Medical Imaging In Healthcare</b>
<b>16.00 – 16.30</b>	<b>Analysing Patient Healthcare Data To Identify Asthmatic Sub-populations</b> <b>Raj Bandaru, Senior Director, Integrated Pharmacology, Sanofi</b>
<b>16.30 – 17.00</b>	<b>The Application Of AI In Pharmacovigilance And Medical Coding</b> <b>Marian Klug, Project Lead, Bayer</b>
<b>17.00</b>	<b>End Of Conference</b>

# Artificial Intelligence in Drug Development Congress

Conference: 27-28 September 2017, London, UK

<http://www.artificialintelligence-congress.com/>

## HOW TO REGISTER:

FAX your booking form to +44(0)1865 250985 | PHONE on +44(0)1865 248455 | EMAIL: [marketing@oxfordglobal.co.uk](mailto:marketing@oxfordglobal.co.uk)

### Delegate Details

Please complete fully and clearly. Please photocopy for additional delegates

Title: \_\_\_\_\_ Forename: \_\_\_\_\_ Surname: \_\_\_\_\_

Job Title: \_\_\_\_\_

Company/Organisation: \_\_\_\_\_

Email: \_\_\_\_\_

Address: \_\_\_\_\_  
\_\_\_\_\_

Postcode: \_\_\_\_\_

Country: \_\_\_\_\_

Direct Telephone \_\_\_\_\_ Direct Fax: \_\_\_\_\_

Mobile: \_\_\_\_\_ Switchboard: \_\_\_\_\_

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Registration Fees

I would like to attend: (Please tick as appropriate)

#### Industry Delegates (Biopharma, Pharma or Biotech Companies)

- Congress £799 plus VAT  
 1 day pass £499 plus VAT  
 Day 1  
 Day 2

#### Academic Delegates

- Congress £499 plus VAT  
 1 day pass £299 plus VAT  
 Day 1  
 Day 2

#### Vendor Delegates

(CROs, Consultants, Technology and Service Providers)

- Congress Only £1350 plus VAT  
 1 day pass £799 plus VAT  
 Day 1  
 Day 2

- Poster Presentation £250 plus VAT

#### PROMOTIONAL LITERATURE DISTRIBUTION

- Distribution of your company's promotional literature to all conference attendees £999 plus VAT

### Terms & Conditions of Booking

Agreed Terms between the Organiser (Oxford Global Marketing Ltd) and the Delegate:

#### Delegate Booking Fee

The Delegate Booking Fee includes: lunches and refreshments throughout the Congress event, conference presentations, workshop and panel sessions, scheduled one-to-one meetings and networking/social events, conference and speaker notes. Delegates may attend, free of charge, all sessions arranged by the Organiser. An admin surcharge of £50 + VAT will be applied to payments settled following the receipt of an invoice. This charge will not be applied to payments settled online.

Vendor Delegates will not be eligible for one to one meetings unless they purchase a sponsorship meetings package. These can only be purchased directly from Oxford Global Marketing Ltd and not via the online booking facility.

#### Poster Presentations

Those who have booked a poster presentation at the event must provide the poster title, abstract (200 words or less), principal author, organisation, mailing address, email, telephone, fax and additional authors, within a month of registration. All poster spaces will be for A0 (841mm x 1189mm) portrait size.

#### Cancellation and Curtailment

Delegates and vendor delegates are subject to the following charges and refunds upon withdrawal or cancellation.

More than 6 months prior 35% cancellation fee / 65% refund  
Between 6 and 3 months prior 75% cancellation fee/ 25% refund  
Less than 3 months prior to the event Full cancellation fee / No refund

#### Data Protection

The data controller is the Organiser. The Organiser may disclose such personal information to Registered Event Sellers (Solution Providers) and other Delegates but solely for the purposes of the Event. The Delegate consents to the use of his/her personal and company information on the terms set out herein.

#### Miscellaneous

This Agreement may not be transferred or assigned by either the Delegate or the Delegate's Company. The Organiser will determine the scope and content of Congress conference events, seminars, workshops and activities throughout the Event. The Organiser reserves the right to cancel the Event without liability to Delegate's Company or individual Delegate. If for any reason the Organiser has to cancel or postpone this Event, the Organiser reserves the right to transfer this Booking to another Congress within the same sector to be held within twelve months. Should another Congress in the same sector not be available within this period, the Booking Fee will be refunded.

I agree to the above Terms and Conditions

### Documentation

- I cannot attend but would like to purchase access to the following:  
 Access to the online conference presentations £499 plus VAT  
 Conference presentations - paper copy £499 plus VAT

VAT is charged at 20% on the attendance fees for all delegates. VAT is also charged on online and paper copy documentation and promotional literature distribution for all UK customers and for those EU customers not supplying a registration number for their own country here.

### How to Pay (choose one of the following payment options)

#### Number of delegates:

Industry del(s)  Academic dels(s)  Vendor dels(s)

#### Special Offer: 3 for 2

*Offer is only valid on the congress and for those registering at Industry or Academic rates*

**CREDIT CARD:**  Visa  MasterCard  Maestro  Amex

Credit Card Number:

Valid from:   /

Expiry Date:   /

Security code:

Cardholders name: \_\_\_\_\_

Signature: \_\_\_\_\_ Date: \_\_\_\_\_

#### PLEASE INVOICE ME:

Invoice Address (if different from above) \_\_\_\_\_

\*Please note there is a £50 plus VAT handling charge for payment via invoice  
\*All card payments will be subject to a 3% bank charge or 4% AMEX charge



If you have any further queries please call the marketing team on +44(0)1865 248455 or email [marketing@oxfordglobal.co.uk](mailto:marketing@oxfordglobal.co.uk)